Ginsenoside F1

Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.

Product Specifications

CAS Number

[53963-43-2]

Product Name Alternative

20 (S) -Ginsenoside F1

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Cytochrome P450; Endogenous Metabolite

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Ginsenoside-F1.html

Purity

99.0

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO)([H])CC4)C

Molecular Formula

C36H62O9

Molecular Weight

638.87

Precautions

H315, H319, H335

References & Citations

[1]Wang DD, et al. Rare ginsenoside Ia synthesized from F1 by cloning and overexpression of the UDP-glycosyltransferase gene from Bacillus subtilis: synthesis, characterization, and in vitromelanogenesis inhibition activity in BL6B16 cells. J Ginseng Res. 2018 Jan;42 (1) :42-49.|[2]Qin M, et al. Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling. Front Pharmacol. 2017 Dec 22;8:953.